Nov 2024
Roche to Acquire Poseida Therapeutics in a Deal Worth Up to $1.5 Billion
Poseida is a public clinical-stage biopharmaceutical company which creates donor-derived CAR-T cell therapies
Nov 2024
Update from Beigene
Shares Up on EU Approval for Gastric, Esophageal Cancer Treatment